Led by Dr. Kendall Smith, professor of medicine and chief of immunology at Weill Cornell, a multicenter-controlled study has shown that low daily doses of Interleukin 2 can be given to patients with chronic HIV infection and low lymphocyte concentrations for as long as six months without severe side effects, leading to an improvement of their immune system. In another study, Dr. Smith and his research team have demonstrated that individuals with chronic HIV who received antivirals plus Interleukin 2 had higher concentrations of circulating killer lymphocytes and lower levels of the HIV virus in their blood. Two separate reports, detailing these findings, were published in the November issue of HIV Clinical Trials.
December 18, 2000
Led by Dr. Kendall Smith, professor of medicine and chief of immunology at Weill Cornell, a multicenter-controlled study has shown that low daily doses of Interleukin 2 can be given to patients with chronic HIV infection and low lymphocyte concentrations for as long as six months without severe side effects, leading to an improvement of their immune system. In another study, Dr. Smith and his research team have demonstrated that individuals with chronic HIV who received antivirals plus Interleukin 2 had higher concentrations of circulating killer lymphocytes and lower levels of the HIV virus in their blood. Two separate reports, detailing these findings, were published in the November issue of HIV Clinical Trials.